ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 247 filers reported holding ACADIA PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 1.36 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $720,668 | -12.5% | 34,581 | +0.5% | 0.00% | 0.0% |
| Q2 2023 | $823,904 | +9.8% | 34,401 | -13.7% | 0.00% | 0.0% |
| Q1 2023 | $750,560 | +18.2% | 39,881 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $634,906 | -18.5% | 39,881 | -16.2% | 0.00% | 0.0% |
| Q3 2022 | $779,000 | +16.1% | 47,611 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $671,000 | -41.8% | 47,611 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $1,153,000 | +3.8% | 47,611 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $1,111,000 | +40.5% | 47,611 | 0.0% | 0.00% | 0.0% |
| Q3 2021 | $791,000 | -31.9% | 47,611 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $1,161,000 | -62.6% | 47,611 | -60.5% | 0.00% | -66.7% |
| Q1 2021 | $3,107,000 | -54.2% | 120,440 | -5.2% | 0.01% | -57.1% |
| Q4 2020 | $6,789,000 | +26.3% | 126,990 | -2.6% | 0.01% | +16.7% |
| Q3 2020 | $5,377,000 | -14.4% | 130,358 | +0.6% | 0.01% | -25.0% |
| Q2 2020 | $6,278,000 | +169.1% | 129,528 | +134.6% | 0.02% | +128.6% |
| Q1 2020 | $2,333,000 | -1.2% | 55,223 | 0.0% | 0.01% | +16.7% |
| Q4 2019 | $2,362,000 | +16.6% | 55,223 | -1.9% | 0.01% | +20.0% |
| Q3 2019 | $2,025,000 | +25.5% | 56,273 | -6.7% | 0.01% | +25.0% |
| Q2 2019 | $1,613,000 | +4.7% | 60,327 | +5.1% | 0.00% | 0.0% |
| Q1 2019 | $1,541,000 | +66.1% | 57,397 | 0.0% | 0.00% | +33.3% |
| Q4 2018 | $928,000 | -22.1% | 57,397 | 0.0% | 0.00% | 0.0% |
| Q3 2018 | $1,192,000 | +36.1% | 57,397 | 0.0% | 0.00% | +50.0% |
| Q2 2018 | $876,000 | -70.6% | 57,397 | -56.8% | 0.00% | -75.0% |
| Q1 2018 | $2,982,000 | -25.9% | 132,727 | -0.7% | 0.01% | -27.3% |
| Q4 2017 | $4,024,000 | -19.1% | 133,627 | +1.2% | 0.01% | -21.4% |
| Q3 2017 | $4,976,000 | +35.1% | 132,087 | 0.0% | 0.01% | +40.0% |
| Q2 2017 | $3,684,000 | -4.1% | 132,087 | +18.3% | 0.01% | -9.1% |
| Q1 2017 | $3,840,000 | +19.4% | 111,697 | +0.2% | 0.01% | +10.0% |
| Q4 2016 | $3,216,000 | -1.3% | 111,511 | +8.9% | 0.01% | 0.0% |
| Q3 2016 | $3,257,000 | +2.0% | 102,377 | +4.1% | 0.01% | 0.0% |
| Q2 2016 | $3,193,000 | +96.0% | 98,377 | +68.9% | 0.01% | +66.7% |
| Q1 2016 | $1,629,000 | -21.6% | 58,261 | 0.0% | 0.01% | -25.0% |
| Q4 2015 | $2,077,000 | +7.8% | 58,261 | 0.0% | 0.01% | +14.3% |
| Q3 2015 | $1,927,000 | -21.0% | 58,261 | 0.0% | 0.01% | -22.2% |
| Q2 2015 | $2,440,000 | +30.1% | 58,261 | +1.3% | 0.01% | +50.0% |
| Q1 2015 | $1,875,000 | +7.3% | 57,523 | +4.5% | 0.01% | +20.0% |
| Q4 2014 | $1,748,000 | +29.4% | 55,057 | +0.9% | 0.01% | +25.0% |
| Q3 2014 | $1,351,000 | +9.7% | 54,557 | 0.0% | 0.00% | 0.0% |
| Q2 2014 | $1,232,000 | +47.0% | 54,557 | +58.5% | 0.00% | +33.3% |
| Q1 2014 | $838,000 | +32.2% | 34,426 | +35.8% | 0.00% | +50.0% |
| Q4 2013 | $634,000 | -9.0% | 25,356 | 0.0% | 0.00% | 0.0% |
| Q3 2013 | $697,000 | +51.5% | 25,356 | 0.0% | 0.00% | 0.0% |
| Q2 2013 | $460,000 | – | 25,356 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 432,317 | $11,154,000 | 4.70% |
| Baker Brothers Advisors | 41,910,704 | $1,081,296,000 | 4.69% |
| Palo Alto Investors LP | 2,337,877 | $60,317,000 | 3.44% |
| Birchview Capital, LP | 177,000 | $4,567,000 | 2.71% |
| Longitude (Cayman) Ltd. | 188,000 | $4,850,000 | 1.86% |
| GREAT POINT PARTNERS LLC | 311,217 | $8,029,000 | 1.66% |
| Avoro Capital Advisors LLC | 2,500,000 | $64,500,000 | 1.11% |
| PFM Health Sciences, LP | 1,302,129 | $33,595,000 | 1.03% |
| HealthCor Management, L.P. | 900,490 | $23,233,000 | 0.82% |
| Eversept Partners, LP | 420,000 | $10,836,000 | 0.82% |